Breast Cancer Res Treat:乳腺钼靶筛查时早期检出乳腺癌相关钙化至关重要

2017-10-30 Aries “肿瘤资讯”微信号

该研究数据来自2003~2014年荷兰乳腺癌筛查项目6万3895例女性筛查队列,其中5万9690例女性筛查未见异常、744例女性既往检查阴性但是筛查检出癌症、781例女性由于钙化为筛查假阳性、413例女性发生间隔癌。

该研究数据来自2003~2014年荷兰乳腺癌筛查项目6万3895例女性筛查队列,其中5万9690例女性筛查未见异常、744例女性既往检查阴性但是筛查检出癌症、781例女性由于钙化为筛查假阳性、413例女性发生间隔癌。

结果发现,钙化筛查的敏感度为45.5%,特异度为99.5%。68.4%的癌症相关钙化与随后确诊的浸润性癌相关。因此恶性钙化的筛查敏感度低。提高这些早期癌症征兆的检出率至关重要。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079886, encodeId=8eea20e98869e, content=<a href='/topic/show?id=38402380666' target=_blank style='color:#2F92EE;'>#乳腺钼靶筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23806, encryptionId=38402380666, topicName=乳腺钼靶筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Thu Jan 11 23:39:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796262, encodeId=82361e96262c3, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Sep 01 03:39:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711234, encodeId=fe371e112343f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Aug 05 11:39:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351099, encodeId=b18813510995e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 01 00:39:00 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079886, encodeId=8eea20e98869e, content=<a href='/topic/show?id=38402380666' target=_blank style='color:#2F92EE;'>#乳腺钼靶筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23806, encryptionId=38402380666, topicName=乳腺钼靶筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Thu Jan 11 23:39:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796262, encodeId=82361e96262c3, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Sep 01 03:39:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711234, encodeId=fe371e112343f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Aug 05 11:39:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351099, encodeId=b18813510995e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 01 00:39:00 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079886, encodeId=8eea20e98869e, content=<a href='/topic/show?id=38402380666' target=_blank style='color:#2F92EE;'>#乳腺钼靶筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23806, encryptionId=38402380666, topicName=乳腺钼靶筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Thu Jan 11 23:39:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796262, encodeId=82361e96262c3, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Sep 01 03:39:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711234, encodeId=fe371e112343f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Aug 05 11:39:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351099, encodeId=b18813510995e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 01 00:39:00 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079886, encodeId=8eea20e98869e, content=<a href='/topic/show?id=38402380666' target=_blank style='color:#2F92EE;'>#乳腺钼靶筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23806, encryptionId=38402380666, topicName=乳腺钼靶筛查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Thu Jan 11 23:39:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796262, encodeId=82361e96262c3, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Sep 01 03:39:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711234, encodeId=fe371e112343f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Aug 05 11:39:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351099, encodeId=b18813510995e, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 01 00:39:00 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
    2017-11-01 zhaojie88

相关资讯

[SIBCS2017]张建国教授:保乳治疗是早期乳腺癌安全的“减法”治疗

中国早期乳腺癌保乳率偏低的重要原因为理念落后,而肿瘤医生有责任向患者传递正确的治疗理念。在第十二届上海乳腺癌论坛会议期间,哈尔滨医科大学附属第二医院张建国教授告诉《肿瘤了望》记者,保乳治疗是早期乳腺癌安全的“减法”治疗。

[SIBCS2017]郝春芳教授:乳腺癌加强内分泌治疗的利害之争

内分泌治疗是乳腺癌综合治疗的重要手段,加强与延长内分泌治疗是近几年的热点问题。2017年10月19-21日,第十二届上海国际乳腺癌论坛(SIBCS)成功举办。《肿瘤瞭望》特邀天津肿瘤医院郝春芳教授对乳腺癌内分泌治疗的热点与难点问题进行了深入解读。

Radiology:人工智能新科技给出答案:到底哪些乳腺高危病变最终将发展为乳腺癌?

机器学习(Machine Learning, ML)是一门多领域交叉学科,专门研究计算机怎样模拟或实现人类的学习行为,以获取新的知识或技能,重新组织已有的知识结构使之不断改善自身的性能。乳腺高危病变是一组临床、病理学和生物学上的异质性疾病,诊断之后乳腺癌发生的危险性增加,但危险程度和水平各异,临床意义与干预策略也不同。

J Clin Oncol:美国临床肿瘤学会指南专项更新:骨改良药物对转移性乳腺癌的作用

美国临床肿瘤学会指南专项更新:有骨转移证据的乳腺癌患者应该接受骨改良药物治疗。

Clin Cancer Res:中国大样本非选择性乳腺癌患者易感基因突变研究

该研究于2003年10月~2015年5月从北京大学肿瘤医院乳腺癌预防治疗中心连续入组中国乳腺癌患者8085例,不对年龄或家族史进行限制,其中91.7%为I~III期原发可手术乳腺癌,使用62基因组对46个癌症易感基因种系突变进行检测。

盘点:近期关于乳腺癌研究进展一览

【1】Nat Commun:科学家开发出抗体-药物共轭物给癌细胞致命打击!斯克里普斯研究所(TSRI)佛罗里达州校区的科学家们创建了一类新的抗体 - 药物共轭物(ADCs),使用了多功能的"双层"技术,将抗体和药物联合在一起,产生高效药物用于癌症治疗。新的ADC技术推进了一类使用抗体选择性地将药物递送至癌细胞而不损害健康细胞和组织的药物。该研究于今天在自然通讯杂志上发表,由TSRI副教授Chr